Luoxin Group is a large enterprise that engages in the pharmaceutical research and development, manufacture, sales, and hospital service. Luoxin Group has its manufacture facility and sale¡¯s organization base in Shandong and set up a world-class research and development center in Zhangjiang, Shanghai. In Shandong Province, the Luoxin Industry Park consists of two plants and eight sections in Luozhuang District, Linyi City; the Hengxin Industry Park consists of three plants and five sections; the logistics facility consists of one division and five sections. The Group's health care industry is developing rapidly.
I. Shanghai Research Center has a professional team consisting of talents from both domestic and abroad. Taking the resource advantage of Shanghai Zhangjiang Hi-Tech Park, the Center conducts the high-end research and training the talents for Luoxin Group, strongly promoting the development of new drugs. At present, there are more than 300 researchers, including 30 staff with doctor degree and more than 150 staff with master degree, and many overseas returnees. Luoxin Group has set up a national-level Postdoctoral Workstation and a joint Engineering Laboratory. The Luoxin Group also cooperated with Shenyang Pharmaceutical University to establish the Postdoctoral Workstation and the Teaching, Intern, and Employment Base for graduates from the University, which facilitates the company's rapid growth.
II. Luoxin Industrial Park's gross floor area is 150,000 m2, consisting of two pharmaceutical production bases: Luoxin Plant and Yuxin Plant. It is divided into office area, R&D and production area, and living quarters. The manufacture facility can produce more than 10 dosage forms, such as injection powder, lyophilized injection powder, large/small volume injections, tablets (including slow-release formulation), capsules (including slow-release formulation), granules, dry suspension, micro-pellets, soft capsules, aerosols, prefilled syringes, etc.
III. The first phase of Hengxin Industrial Park has a floor area of 50,000 m2, consisting of office area, BPC (Bulk Pharmaceutical Chemical) production area, traditional Chinese medicine area, medical apparatus area, and living quarters. The BPC production area can produce common oral and sterile chemical APIs, anti-tumor APIs, oral and sterile cephalosporin, and extraction of Chinese traditional medicines.
IV. Luoxin Pharmaceutical Group has established logistics companies in North China, Northwest China, South China, East China, and Shandong Province, which connect with the local liaisons in various cities to form an efficient distribution network.
V. In terms of the health care service, Luoxin Group is speeding up the construction of hospitals, nursing homes, and the health product manufacture base. At present, the 2nd Feixian Hospital invested by the Group has been put into use.
Luoxin Group's industrial layout is expanding rapidly.